Skip to main content

Table 6 Outcomes after SIT

From: Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis

Characteristics Failed steroid tapering after SIT IMC recurrence
OR (95% CI) P OR (95% CI) P
ICI type
Anti-PD-1/L1 monotherapy Reference   Reference  
Anti-CTLA-4 therapy 0.50 (0.19–1.29) 0.150 1.09 (0.36–3.37) 0.871
Colitis grade
1–2 Reference   Reference  
3–4 4.09 (1.53–10.98) 0.005 1.79 (0.59–3.38) 0.299
Multiple hospitalizations 9.05 (2.79–29.33) < 0.001 26.25 (3.22–213.82) 0.002
Failed steroid tapering before SIT 3.75 (1.39–10.16) 0.009 2.42 (0.75–7.77) 0.138
Failed steroid tapering after SIT 4.07 (1.29–12.88) 0.017
Type of SIT
Vedolizumab Reference   Reference  
Infliximab 0.47 (0.18–1.22) 0.120 12.57 (1.57–100.57) 0.017
No. of SIT infusions
1–2 Reference   Reference  
≥3 2.97 (1.13–7.79) 0.027 0.09 (0.01–0.72) 0.023
Endoscopic remission 1.68 (0.41–6.96) 0.474 0.15 (0.03–0.79) 0.025
Histologic remission 0.67 (0.18–2.46) 0.543 0.18 (0.04–0.88) 0.033
Number of steroids tapering attempts 9.50 (3.76–24.01) < 0.001 3.35 (1.68–6.69) 0.001
Duration from IMC onset to SIT 1.05 (1.01–1.09) 0.011 1.00 (0.98–1.03) 0.774
Overall duration of steroids 1.02 (1.01–1.04) 0.001 1.01 (1.00–1.03) 0.022
Calprotectin at time of onset 1.00 (0.99–1.00) 0.599 1.00 (0.99–1.01) 0.346
Calprotectin after SIT 1.00 (0.99–1.00) 0.573 1.01 (1.00–1.01) 0.014
Duration of hospitalization 1.12 (1.04–1.21) 0.004 1.14 (1.05–1.23) 0.001
Duration of symptoms 1.06 (1.03–1.08) < 0.001 1.02 (1.01–1.03) 0.008
  1. Abbreviations: CI, confidence interval; CTLA, cytotoxic T lymphocyte associated protein; SIT, selective immunosuppressive therapy; OR, odds ratio; PD-1, programmed death protein 1; PD-L1, PD-1 ligand